Clinical Trials on Mild to Moderate Plaque Psoriasis in Japan

Total 42 results

Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Clinical Study of KHK4827

Moderate to Severe Plaque Psoriasis

Japan
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Moderate to Severe Plaque-type Psoriasis

United States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Plaque Psoriasis | Psoriatic Arthritis | Psoriatic Erythroderma | Pustular Psoriasis (Excluding a Localized)

Japan
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Bristol-Myers Squibb

Recruiting

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) (RePhlect)

Plaque Psoriasis

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Coherus Biosciences, Inc.
Shire; Daiichi Sankyo Co., Ltd.

Completed

A Long Term Safety Extension Study (CHS-0214-05)

Rheumatoid Arthritis | Plaque Psoriasis

Japan
AstraZeneca
Johnson & Johnson

Completed

Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy (Kagami_SDS)

Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy

Japan
Novartis Pharmaceuticals

Completed

Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A

Plaque Psoriasis

Japan
Amgen

Completed

A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

Plaque Psoriasis

Japan, Germany
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Puerto Rico, United States, Germany, Poland, Japan, Canada
Amgen

Recruiting

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Japan
Novartis Pharmaceuticals

Completed

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. (ENA1stepswitch)

Mild to Moderate Alzheimer's Disease

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis (FRONTIER 2)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Taiwan, Japan, Spain, United Kingdom, Poland, Canada
Novartis Pharmaceuticals

Completed

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Chronic Plaque-type Psoriasis

United States, Estonia, Japan, Latvia, Canada, Iceland
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Australia, Mexico, Canada, United Kingdom, France, Argentina, Japan, Poland, Spain, Korea, Republic of, Brazil, Germany, Romania
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis (FRONTIER 1)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Canada, Japan, Taiwan, Spain, United Kingdom, Poland
Takeda

Recruiting

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Plaque Psoriasis

United States, Canada, Poland, Italy, Japan
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 2)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
UCB Biopharma S.P.R.L.
Parexel

Completed

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 1)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)

Plaque-type Psoriasis

United States, Austria, Germany, France, Japan, Canada, Slovakia, India
Eli Lilly and Company

Completed

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

Plaque Psoriasis

Argentina, Puerto Rico, United States, Australia, Taiwan, Japan, Hungary, Korea, Republic of, Mexico, Germany, Poland, Romania, Czechia, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

Plaque Psoriasis

Germany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Australia, Spain, Argentina, Japan
Novartis Pharmaceuticals

Completed

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Plaque-type Psoriasis

Germany, United States, Japan, France, Norway, Israel, Iceland
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Korea, Republic of, United Kingdom, United States, Poland, Germany, Brazil, Spain, Taiwan, Hungary, Japan, Canada, Argentina, Australia
Novartis Pharmaceuticals

Completed

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Chronic Plaque-type Psoriasis

Germany, United States, Japan, France, Israel, Norway, Iceland
Novartis Pharmaceuticals

Completed

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Chronic Severe Plaque-type Psoriasis

Belgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
AbbVie

Active, not recruiting

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

Chronic Plaque Psoriasis

Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Moderate to Severe Atopic Hand and Foot Dermatitis

United States, Germany, Japan, Poland
Kyowa Kirin Co., Ltd.

Active, not recruiting

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Moderate to Severe Systemic Sclerosis

Japan
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Moderate to Severe Asthma

Korea, Republic of, United States, Spain, Poland, Japan, Canada, Germany, Belgium, Argentina
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
City of Hope Medical Center

Recruiting

Early Detection of Advanced Adenomas and Colorectal Cancer (AACRC)

Colorectal Neoplasms | Colorectal Cancer | Colorectal Disorders | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Adenomatous Polyp | Colorectal Cancer Stage I | Colorectal Adenoma... and other conditions

United States, Italy, China, Spain, Japan

Clinical Trials on Mild to Moderate Plaque Psoriasis in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations